Clinical Trials Directory

Trials / Completed

CompletedNCT03158142

The Influence of Atropine on Choroidal Thickness

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
32 (actual)
Sponsor
State University of New York College of Optometry · Academic / Other
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

Atropine eye drops are increasingly prescribed for the management of progressive myopia or short-sightedness. A previous study suggested that the back of the eye or choroid may be a part of the mechanism by which it induces its effects. The aim of this study is to characterize the effects of atropine on choroidal thickness and the influence of time of administration (am vs pm). It is hypothesized that the atropine's effect on choroidal thickness will vary with baseline thickness related to diurnal rhythm, where thicker baseline thickness will show a reduced choroidal response.

Detailed description

Atropine eye drops are increasingly prescribed for the management of progressive myopia or short-sightedness. A previous study suggested that the back of the eye or choroid may be a part of the mechanism by which it induces its effects. The choroid shows diurnal variation and the efficacy of atropine on myopia control in relationship to the patient's baseline choroidal thickness is unknown. Thus, the objective of this study is to provide data to characterize the influence of atropine on choroid thickness. The study aims are to: 1. Determine the effect of am or pm atropine application on choroid thickness 2. Determine the effect of atropine on choroid thickness in relationship to baseline thickness Participants will be asked to attend a screening session and 13 study visits. Following the screening visit, participants will be scheduled to return for 4 visits across 12 hours (4 hour intervals starting from 8am) in a single day where eye shape measurements will be taken to characterize diurnal variations in eye shape. Subjects will then be randomized to receive a drop of 1% atropine eye drops in both eyes in the morning or a night. Measurements of the shape of the front and back of the eye will be taken after approximately 1, 12, 24 and 96 hours after drop instillation. After a 2 week washout period, 1% atropine eye drops will be administered either in the morning or at night (the visit that was not previously scheduled) and measurements of the shape of the front and back of the eye will be taken after approximately 1, 12, 24 and 96 hours after drop instillation.

Conditions

Interventions

TypeNameDescription
DRUGAtropine Sulfate 1% Oph SolnAtropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic

Timeline

Start date
2017-03-15
Primary completion
2017-11-20
Completion
2017-11-20
First posted
2017-05-17
Last updated
2018-10-15

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03158142. Inclusion in this directory is not an endorsement.